^
    over1year
    A phase Ia trial to evaluate the safety and efficacy of HB0030, an anti-TIGIT antibody, in patients with advanced solid tumors: Preliminary results. (ASCO 2023)
    HB0030 showed very well safety in the stage of dose escalation from 0.1 to 20 mg/kg, and potential promising anti-tumor activity above 3mg/kg dose in advanced solid tumors pts, especially in NSCLC. Currently, 30mg/kg and 40mg/kg dose escalation are ongoing. Clinical trial information: NCT05706207.
    Clinical • P1 data • IO biomarker • Metastases
    |
    TP53 (Tumor protein P53) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    TP53 mutation
    |
    HB0030